Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue estimate for the current year. Neogen NEOG is likely to post revenue of $235.22 million in the year ending May, 2014. Neogen's PEG ratio is 2.85. Analysts expect Meridian Bioscience VIVO to post revenue of $204.53 million for the year ending September, 2014. Meridian Bioscience's trailing-twelve-month ROE is 25.63%. Quidel QDEL is expected to report revenue of $173.74 million for the year ending December, 2013. Quidel had $10.25 million in total cash for the latest quarter. Abaxis ABAX may report revenue of $188.65 million in the year ending March, 2014. Abaxis's trailing-twelve-month operating margin is 14.31%.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Trading IdeasDiagnostic Substances Industryrevenue estimatesSmall capssmall-cap
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!